Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Salvianolic acid B ameliorates non-alcoholic fatty liver disease by inhibiting hepatic lipid accumulation and NLRP3 inflammasome in ob/ob mice
Authors
Keywords
-
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 111, Issue -, Pages 109099
Publisher
Elsevier BV
Online
2022-08-04
DOI
10.1016/j.intimp.2022.109099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non-alcoholic fatty liver disease
- (2021) Elizabeth E Powell et al. LANCET
- Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
- (2021) Oriol Juanola et al. International Journal of Environmental Research and Public Health
- Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach
- (2021) Giovanni Targher et al. Lancet Gastroenterology & Hepatology
- Salvianolic acid B improved insulin resistance through suppression of hepatic ER stress in ob/ob mice
- (2020) Yanan Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis
- (2020) Susanne Gaul et al. JOURNAL OF HEPATOLOGY
- Tanshinone IIA reduces palmitate‐induced apoptosis via inhibition of endoplasmic reticulum stress in HepG2 liver cells
- (2019) Junjian Wang et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Tanshinone IIA ameliorates non-alcoholic fatty liver disease through targeting peroxisome proliferator-activated receptor gamma and toll-like receptor 4
- (2019) Lu Huang et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
- (2019) Xinyang Yu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma
- (2019) Li Che et al. Frontiers in Oncology
- Preclinical models of non-alcoholic fatty liver disease
- (2018) Prasanna K. Santhekadur et al. JOURNAL OF HEPATOLOGY
- Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release
- (2018) Junjiang Pan et al. CELLULAR IMMUNOLOGY
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Xylanase and Fermented Polysaccharide of Hericium caputmedusae Reduce Pathogenic Infection of Broilers by Improving Antioxidant and Anti-Inflammatory Properties
- (2018) Sitong Zhang et al. Oxidative Medicine and Cellular Longevity
- Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation
- (2018) Xiao-Xiao Li et al. BIOMEDICINE & PHARMACOTHERAPY
- Fatty acid synthase (FASN) as a therapeutic target in breast cancer
- (2017) Javier A. Menendez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
- (2017) Auvro R. Mridha et al. JOURNAL OF HEPATOLOGY
- Modelling immune–microbe interaction in 3D intestinal culture
- (2017) Hugh Thomas Nature Reviews Gastroenterology & Hepatology
- Conophylline inhibits non-alcoholic steatohepatitis in mice
- (2017) Yukiomi Nakade et al. PLoS One
- ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
- (2016) Paul Y Kwo et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Tetrandrine has anti-adipogenic effect on 3T3-L1 preadipocytes through the reduced expression and/or phosphorylation levels of C/EBP-α, PPAR-γ, FAS, perilipin A, and STAT-3
- (2016) Byeong-Churl Jang BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children
- (2016) David E. Kleiner et al. Clinics in Liver Disease
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?
- (2016) Christopher D. Byrne et al. DIABETOLOGIA
- Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice
- (2016) Qin Kong et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism
- (2016) Xingyong Wan et al. JOURNAL OF HEPATOLOGY
- Management of NAFLD: a stage-based approach
- (2016) Mary E. Rinella et al. Nature Reviews Gastroenterology & Hepatology
- Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
- (2016) Xingyong Wan et al. Canadian Journal of Gastroenterology and Hepatology
- The Inflammasomes and Autoinflammatory Syndromes
- (2015) Lori Broderick et al. Annual Review of Pathology-Mechanisms of Disease
- Reactive Oxygen Species-Induced TXNIP Drives Fructose-Mediated Hepatic Inflammation and Lipid Accumulation Through NLRP3 Inflammasome Activation
- (2015) Xian Zhang et al. ANTIOXIDANTS & REDOX SIGNALING
- Sodium tanshinone IIA sulfonate ameliorates ischemia-induced myocardial inflammation and lipid accumulation in Beagle dogs through NLRP3 inflammasome
- (2015) Qinghua Hu et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction
- (2015) Huilin Hu et al. PHARMACEUTICAL BIOLOGY
- NLRP3 inflammasome and its inhibitors: a review
- (2015) Bo-Zong Shao et al. Frontiers in Pharmacology
- Tanshinone IIA Downregulates HMGB1 and TLR4 Expression in a Spinal Nerve Ligation Model of Neuropathic Pain
- (2014) Yu-Qing Ma et al. Evidence-based Complementary and Alternative Medicine
- SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease
- (2014) Motoyuki Kohjima et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis
- (2014) Xiang Zhang et al. JOURNAL OF HEPATOLOGY
- NLRP3 inflammasome activation is required for fibrosis development in NAFLD
- (2014) Alexander Wree et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
- (2014) Fernando J. Barreyro et al. LIVER INTERNATIONAL
- Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae
- (2013) Thomas Karlas et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- The liver X receptor: A master regulator of the gut–liver axis and a target for non alcoholic fatty liver disease
- (2013) Simon Ducheix et al. BIOCHEMICAL PHARMACOLOGY
- Diets and nonalcoholic fatty liver disease: The good and the bad
- (2013) Mohamed Asrih et al. CLINICAL NUTRITION
- The NLRP3 Inflammasome as a Novel Player of the Intercellular Crosstalk in Metabolic Disorders
- (2013) Elisa Benetti et al. MEDIATORS OF INFLAMMATION
- From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
- (2013) Alexander Wree et al. Nature Reviews Gastroenterology & Hepatology
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
- (2012) Naga Chalasani et al. GASTROENTEROLOGY
- Elovl6 promotes nonalcoholic steatohepatitis
- (2012) Takashi Matsuzaka et al. HEPATOLOGY
- Inflammasomes in liver diseases
- (2012) Gyongyi Szabo et al. JOURNAL OF HEPATOLOGY
- Inflammasomes in health and disease
- (2012) Till Strowig et al. NATURE
- Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
- (2012) Jorge Henao-Mejia et al. NATURE
- Sensing and reacting to microbes through the inflammasomes
- (2012) Luigi Franchi et al. NATURE IMMUNOLOGY
- Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
- (2012) Marcelo O. Dietrich et al. NATURE REVIEWS DRUG DISCOVERY
- Tanshinone IIA Attenuates the Inflammatory Response and Apoptosis after Traumatic Injury of the Spinal Cord in Adult Rats
- (2012) Xin Yin et al. PLoS One
- Endpoints and clinical trial design for nonalcoholic steatohepatitis
- (2011) Arun J. Sanyal et al. HEPATOLOGY
- Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells
- (2011) Timea Csak et al. HEPATOLOGY
- Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans
- (2011) Jussi Pihlajamäki et al. JOURNAL OF HEPATOLOGY
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
- (2011) Bolormaa Vandanmagsar et al. NATURE MEDICINE
- Recent advances in nonalcoholic fatty liver disease
- (2010) Onpan Cheung et al. CURRENT OPINION IN GASTROENTEROLOGY
- Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection
- (2010) Brad Q. Starley et al. HEPATOLOGY
- Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
- (2009) Curtis K. Argo et al. Clinics in Liver Disease
- The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS
- (2009) Guan-Wei Fan et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease
- (2008) Hironori Mitsuyoshi et al. HEPATOLOGY RESEARCH
- Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
- (2008) G MUSSO et al. PROGRESS IN LIPID RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started